Cosciens Biopharma Inc. Files 6-K Report
Ticker: CSCIF · Form: 6-K · Filed: May 13, 2025 · CIK: 1113423
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, company-name-change
TL;DR
Cosciens Biopharma (formerly Aeterna Zentaris) filed a 6-K, standard foreign issuer update.
AI Summary
Cosciens Biopharma Inc. filed a Form 6-K on May 13, 2025. The filing is a report of a foreign private issuer. The company was formerly known as Aeterna Zentaris Inc. and Aeterna Laboratories Inc. Its principal executive office is located in Toronto, Ontario, Canada.
Why It Matters
This filing provides an update on Cosciens Biopharma Inc.'s status as a foreign private issuer, which is relevant for investors tracking regulatory disclosures.
Risk Assessment
Risk Level: low — This filing is a routine administrative update and does not contain material financial or operational news.
Key Players & Entities
- COSCIENS Biopharma Inc. (company) — Filer
- Aeterna Zentaris Inc. (company) — Former company name
- AETERNA LABORATORIES INC (company) — Former company name
- Norton Rose Fulbright Canada, LLP (company) — Legal counsel/address provider
- 20250513 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, providing information that the issuer has made or is required to make public in its home country or otherwise.
When was this Form 6-K filed?
This Form 6-K was filed on May 13, 2025.
What were the previous names of Cosciens Biopharma Inc.?
Cosciens Biopharma Inc. was formerly known as Aeterna Zentaris Inc. and Aeterna Laboratories Inc.
Where is Cosciens Biopharma Inc.'s principal executive office located?
Its principal executive office is located at c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.
Does Cosciens Biopharma Inc. file annual reports under Form 20-F or 40-F?
The registrant indicates it files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 13, 2025 regarding COSCIENS Biopharma Inc. (CSCIF).